• Consensus Rating: Moderate Buy
  • Consensus Price Target: $74.88
  • Forecasted Upside: -15.92%
  • Number of Analysts: 9
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$89.05
▲ +0.06 (0.07%)

This chart shows the closing price for NUVL by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Nuvalent Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NUVL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NUVL

Analyst Price Target is $74.88
▼ -15.92% Downside Potential
This price target is based on 9 analysts offering 12 month price targets for Nuvalent in the last 3 months. The average price target is $74.88, with a high forecast of $105.00 and a low forecast of $42.00. The average price target represents a -15.92% upside from the last price of $89.05.

This chart shows the closing price for NUVL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 9 investment analysts is to moderate buy stock in Nuvalent. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
9/5/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
12/4/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
3/4/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
6/2/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
8/31/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
11/29/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
1/28/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
2/27/2024

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/28/2024BMO Capital MarketsBoost TargetOutperform ➝ Outperform$93.00 ➝ $102.00N/A
2/28/2024GuggenheimInitiated CoverageBuy$99.00Low
2/27/2024WedbushReiterated RatingOutperform$99.00Low
2/23/2024Robert W. BairdInitiated CoverageOutperform$105.00Low
2/22/2024Leerink PartnrsReiterated RatingMarket PerformLow
2/12/2024WedbushReiterated RatingOutperform$82.00 ➝ $99.00Low
1/8/2024WedbushReiterated RatingOutperform$74.00 ➝ $82.00Low
11/14/2023WedbushReiterated RatingOutperform$74.00Low
10/19/2023BMO Capital MarketsBoost TargetOutperform ➝ Outperform$73.00 ➝ $79.00Low
10/5/2023JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$51.00 ➝ $68.00Low
10/5/2023BMO Capital MarketsBoost TargetOutperform ➝ Outperform$52.00 ➝ $73.00Low
10/4/2023WedbushBoost Target$53.00 ➝ $65.00Low
10/4/2023Stifel NicolausReiterated RatingBuyLow
9/26/2023Stifel NicolausInitiated CoverageBuy$65.00Low
9/11/2023WedbushReiterated RatingOutperform$53.00Low
8/10/2023WedbushReiterated RatingOutperform$53.00Low
8/8/2023Leerink PartnrsReiterated RatingMarket PerformLow
8/8/2023SVB LeerinkInitiated CoverageMarket Perform$42.00Low
8/8/2023SVB SecuritiesInitiated CoverageMarket Perform$42.00Low
7/24/2023GuggenheimInitiated CoverageBuy$56.00Low
7/20/2023WedbushReiterated RatingOutperform ➝ Outperform$53.00Low
1/17/2023WedbushInitiated CoverageOutperform$39.00Low
10/28/2022BMO Capital MarketsBoost TargetBuy$28.00 ➝ $50.00Low
6/23/2022BMO Capital MarketsInitiated CoverageOutperform$28.00Low
8/23/2021JPMorgan Chase & Co.Initiated CoverageOverweight$34.00High
8/23/2021CowenInitiated CoverageOutperformHigh
8/23/2021Piper SandlerInitiated CoverageOverweight$40.00High
(Data available from 2/28/2019 forward)

News Sentiment Rating

0.38 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/2/2023
  • 5 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
9/1/2023
  • 8 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
10/1/2023
  • 3 very positive mentions
  • 12 positive mentions
  • 3 negative mentions
  • 3 very negative mentions
10/31/2023
  • 0 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
11/30/2023
  • 7 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
12/30/2023
  • 4 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/29/2024
  • 9 very positive mentions
  • 18 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
2/28/2024

Current Sentiment

  • 9 very positive mentions
  • 18 positive mentions
  • 3 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Nuvalent logo
Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase ½ clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is ongoing IND-enabling studies. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $89.05
Low: $87.83
High: $89.29

50 Day Range

MA: $77.58
Low: $70.51
High: $88.99

52 Week Range

Now: $89.05
Low: $23.09
High: $89.35

Volume

22,971 shs

Average Volume

331,995 shs

Market Capitalization

$5.58 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.37

Frequently Asked Questions

What sell-side analysts currently cover shares of Nuvalent?

The following Wall Street analysts have issued research reports on Nuvalent in the last twelve months: BMO Capital Markets, Guggenheim, JPMorgan Chase & Co., Leerink Partnrs, Robert W. Baird, Stifel Nicolaus, SVB Leerink LLC, SVB Securities, and Wedbush.
View the latest analyst ratings for NUVL.

What is the current price target for Nuvalent?

8 Wall Street analysts have set twelve-month price targets for Nuvalent in the last year. Their average twelve-month price target is $74.88, suggesting a possible downside of 15.9%. Robert W. Baird has the highest price target set, predicting NUVL will reach $105.00 in the next twelve months. SVB Leerink LLC has the lowest price target set, forecasting a price of $42.00 for Nuvalent in the next year.
View the latest price targets for NUVL.

What is the current consensus analyst rating for Nuvalent?

Nuvalent currently has 3 hold ratings and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for NUVL.

What other companies compete with Nuvalent?

How do I contact Nuvalent's investor relations team?

The company's listed phone number is 857-357-7000 and its investor relations email address is [email protected]. The official website for Nuvalent is www.nuvalent.com. Learn More about contacing Nuvalent investor relations.